Prevention strategies for chemotherapy-induced hand-foot syndrome: A systematic review and meta-analysis of prospective randomised trials

Supportive Care in Cancer

Volumn 22, Issue 6, 2014, Pages 1585-1593

  Macedo, Lígia Traldi ^a   Lima, Joao Paulo Nogueira ^a,b   Dos Santos, Lucas Vieira ^a,c,d   Sasse, Andre Deeke ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Barretos Cancer Hospital   (Brazil)

^c Instituto HEMOMED   (Brazil)

^d Clinical Research Unit Instituto de Ensino e Pesquisa São Lucas   (Brazil)

Author keywords

Drug therapy; Hand foot syndrome; Meta analysis; Secondary prevention

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIPERSPIRANT AGENT; CAPECITABINE; CELECOXIB; COD LIVER OIL; CORTICOSTEROID; DEXAMETHASONE; DEXPANTHENOL; DOCETAXEL; DOXORUBICIN; LACTIC ACID; PYRIDOXINE; SORAFENIB; URACIL; UREA;

ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED HAND FOOT SYNDROME; CLINICAL EFFECTIVENESS; DATA BASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TREATMENT FAILURE; HAND FOOT SYNDROME; HUMAN; INDUCED HYPOTHERMIA; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; HAND-FOOT SYNDROME; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84902346834     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2129-z     Document Type: Article

References (42)

1. Almeida da Cruz L, Hoff PM, Ferrari CL, Riechelmann RS (2012) Unilateral hand-foot syndrome: does it take sides? Case report and literature review. Clin Colorectal Cancer 11:82-84
2. Hoesly FJ, Baker SG, Gunawardane ND, Cotliar JA (2011) Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature. Arch Dermatol 147:1418-1423
3. Belum VR, Wu S, Lacouture ME (2013) Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 31:1078-1086
4. Fischer A, Wu S, Ho AL, Lacouture ME (2013) The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 31:787-797
5. Balagula Y, Wu S, Su X et al (2012) The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 30:1773-1781
6. Chu D, Lacouture ME, Weiner E, Wu S (2009) Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 7:11-19
7. Lin E, Morris JS, Ayers GD (2002) Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 16:31-37
8. Fitzpatrick JE (1993) The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol 20:1-14
9. Jacobi U, Waibler E, Schulze P et al (2005) Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 16:1210-1211 (Pubitemid 41418329)
10. Sibaud V, Dalenc F, Chevreau C et al (2011) HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 16:1469-1478
11. von Moos R, Thuerlimann BJ, Aapro M et al (2008) Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 44:781-790
12. Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181 (Pubitemid 36962641)
13. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634 (Pubitemid 27387172)
14. Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54:1046-1055 (Pubitemid 32888370)
15. Review Manager v5.1. In 5.1 Edition. Cochrane Collaboration 2011; http://ims.cochrane.org/revman
16. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1-e34
17. Braik T, Yim B, Evans AT et al. A randomized trial to determine if vitamin B6 can prevent hand and foot syndrome in cancer patients treated with capecitabine chemotherapy. J Clin Oncol 2012; 30 (suppl; abstr 9085)
18. Corrie PG, Bulusu R, Wilson CB et al (2012) A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. Br J Cancer 107:585-587
19. Fabi A, Metro G, Papaldo P et al (2008) Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemother Pharmacol 62:717-725
20. Kang YK, Lee SS, Yoon DH et al (2010) Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 28:3824-3829
21. Kanis M, Kesterson JP, Lele S (2009) The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia. Eur J Gynaecol Oncol 30:387-388
22. Kluschke F, Martschick A, Darvin ME et al (2012) Application of an ointment with high radical protection factor as a prevention strategy against PPE. J Clin Oncol; 30 (suppl; abstr 5064)
23. Kohne CH, DeGreve J, Hartmann JT et al (2008) Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 19:920-926 (Pubitemid 351627308)
24. Lyass O, Lotem M, Edelmann D et al (2001) Protective effect of amifostine (AMF) on doxil/caelyx-induced palmar-plantar erythrodysesthesia (PPE) in patients (pts) with advanced cancer. Proc Am Soc, Clin Oncol; 20:(abstr 2148)
25. Mangili G, Petrone M, Gentile C et al (2008) Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 108:332-335
26. Ren Z, Zhu K, Kang H et al (2012) A randomized controlled phase II study of the prophylactic effect of urea-based creamon the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma. J Clin Oncol; 30 (suppl; abstr 4008)
27. Ruhstaller T, Ribi K, Sun H et al (2012) Prevention of palmoplantar erythrodysesthesia (PPE) with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (PLD), a placebo-controlled, double blinded, phase lll trial (SAKK 92/08). J Clin Oncol; 30 (suppl; abstr 9059)
28. von Gruenigen V, Frasure H, Fusco N et al (2010) A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 116:4735-4743
29. Wolf SL, Qin R, Menon SP et al (2010) Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 28:5182-5187
30. Yoshimoto N, Yamashita T, Fujita T et al (2010) Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Breast Cancer 17:298-302
31. Zhang RX, Wu XJ, Lu SX et al (2011) The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol 137:953-957
32. Zhang RX, Wu XJ, Wan DS et al (2012) Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 23:1348-1353
33. Kawaguchi K, Ishiguro H, Morita S et al (2011) Correlation between docetaxel-induced skin toxicity and the use of steroids and H(2) blockers: a multi-institution survey. Breast Cancer Res Treat 130:627-634
34. Nardone B, Hensley JR, Kulik L et al (2012) The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol 11:e61-e65
35. Gressett SM, Stanford BL, Hardwicke F (2006) Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 12:131-141 (Pubitemid 44696441)
36. Rose PG (2005) Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10:205-214
37. Adams RA, Meade AM, Madi A et al (2009) Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 100:251-258
38. Maughan TS, Adams RA, Smith CG et al (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377:2103-2114
39. Johnsen SP, Larsson H, Tarone RE et al (2005) Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 165:978-984 (Pubitemid 40638117)
40. Chen YF, Jobanputra P, Barton P et al (2008) Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess; 12: 1-278, iii
41. Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779-4786 (Pubitemid 350086481)
42. Fabian CJ, Molina R, Slavik M et al (1990) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 8:57-63 (Pubitemid 20087245)